Antibiotic Treatment for Skin Infections
Oral Antibiotic Options
- The Infectious Diseases Society of America recommends clindamycin as the only single oral agent that covers both MRSA and beta-hemolytic streptococci, making it ideal when dual coverage is needed 1, 2, 3
- Clindamycin dosing is 300-450 mg PO three times daily for adults, with a higher risk of Clostridioides difficile infection compared to other oral agents 3, 4
- Approximately 50% of MRSA strains have inducible or constitutive clindamycin resistance, making it a major caveat for its use 5, 4
- The American College of Emergency Physicians suggests that TMP-SMX (1-2 DS tablets PO BID) plus a beta-lactam (penicillin, cephalexin, or amoxicillin) provides reliable dual coverage 1, 2
- Doxycycline (100 mg PO BID) plus a beta-lactam is an equally effective alternative combination for dual coverage 1, 2
Intravenous Options for Severe Infections
- The Society for Healthcare Epidemiology of America recommends vancomycin (15-20 mg/kg/dose IV every 8-12 hours) as the standard IV option for hospitalized patients requiring dual coverage 1, 3
- Linezolid (600 mg IV/PO BID) provides excellent coverage for both MRSA and streptococci with the advantage of seamless IV-to-oral transition 1
- Daptomycin (4-10 mg/kg/dose IV once daily) is effective for complicated skin infections 1, 3
Treatment Duration and Monitoring
- The Infectious Diseases Society of America recommends a standard duration of 5-10 days for uncomplicated infections 3, 4
- Extended duration of 7-14 days for complicated infections is based on clinical response 1, 3
- Reassessing within 48-72 hours is crucial to ensure appropriate response to therapy 3
- Progression despite antibiotics suggests either resistant organisms or a deeper, more serious infection than initially recognized 5
Critical Clinical Pitfalls
- Beta-lactam antibiotics alone (penicillins, cephalosporins) are completely ineffective against MRSA and should never be used as monotherapy when MRSA is suspected 4
- Never use rifampin as monotherapy or adjunctive therapy for skin infections due to rapid resistance development 4
- Obtaining cultures from purulent drainage before starting antibiotics is essential to confirm pathogens and guide definitive therapy 3, 4
- Incision and drainage is the cornerstone of treatment for abscesses—antibiotics alone are insufficient 3, 4
Oral Antibiotic Treatment for Streptococci and MRSA Infections
Single-Agent and Combination Therapy Options
- The 2018 WSES/SIS-E consensus guidelines recommend combination therapy with TMP-SMX or doxycycline plus a beta-lactam for reliable dual coverage of streptococci and MRSA, due to concerns about clindamycin resistance 6
- Local resistance patterns should be checked before prescribing clindamycin, as resistance is now very common 6
Alternative Single-Agent Options for MRSA-Only Coverage
- Linezolid 600 mg PO BID is a Grade 1A recommendation for MRSA skin and soft tissue infections, with excellent bioavailability and superior clinical and microbiological cure rates compared to vancomycin 6, 7
- Tedizolid 200 mg PO once daily is a Grade 1A recommendation, offering a newer oxazolidinone with once-daily dosing advantage 6, 7